Wilson Sonsini Goodrich & Rosati has advised Foresight Diagnostics, and Gibson Dunn has advised Natera, Inc. Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA...
Natera Acquires Foresight Diagnostics in $450 Million All-Stock Transaction
Idorsia’s Reacquisition of Global Rights to Aprocitentan
Wilson Sonsini Goodrich & Rosati represented Idorsia in the transaction. Idorsia Ltd (SIX:IDIA) announced that it entered into an agreement with Janssen Biotech Inc., one of...
Foresight Diagnostics’ $58.75 Million Series B Financing Round
Wilson Sonsini Goodrich & Rosati advised Foresight on the deal. Foresight Diagnostics, Inc, a leading developer of ultrasensitive cancer detection tests, announced the close of an...



























